Skip to main content

Advertisement

Fig. 3 | Breast Cancer Research

Fig. 3

From: Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression

Fig. 3

a In IBC, 64.2% (68/106) of the patients have ≥ 10% infiltration of the stroma with sTIL vs. 70.4% (100/142) of the nIBC patients (P = NS). b There is no significant difference in sTIL infiltration between IBC and nIBC in the luminal and TN subgroup. In the HER2+ group, 100% (16/16) of the nIBC patients have ≥ 10% infiltration of the stroma vs. 72.7% (16/22) of the IBC patients (χ2 = 16.2, P < 0.001). c In IBC, 42.9% (45/105) of the patients have ≥ 1% PD-L1 expression on the infiltrating immune cells vs. 23.7% (33/139) in nIBC (χ2 = 12.5, P = 0.006). d Luminal subtype: ≥ 1% PD-L1 expression in IBC 32.8% (20/61) vs. nIBC 22.8% (18/79) (χ2 = 8.2, P = 0.04). HER2+ subtype: ≥ 1% PD-L1 expression in IBC 52.4% (11/21) vs. nIBC 34.6% (9/26) (P = NS). TN subtype: ≥ 1% PD-L1 expression in IBC 60.9% (14/23) vs. nIBC 17.6% (6/34) (χ2 = 13.4, P = 0.004)

Back to article page